The effects of anti-lung cancer in nude mice by a fully human single-chain antibody against associated antigen Ts7TMR between A549 cells and Trichinella spiralis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. PMID: 33538338. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Skribek M, Rounis K, Tsakonas G, et al. Complications following novel therapies for non-small cell lung cancer. J Intern Med. 2022;291(6):732–754. PMID: 35032058. doi: 10.1111/joim.13445.
   PubMed Web of Science ®Google Scholar
• Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–1506. PMID: 30275569. doi: 10.1038/s41591-018-0146-z.
   PubMed Web of Science ®Google Scholar
• de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer. 2016;68:134–147. PMID: 27755997. doi: 10.1016/j.ejca.2016.09.010.
   PubMed Web of Science ®Google Scholar
• Sadek NL, Costa BA, Nath K, et al. CAR T-cell therapy for multiple myeloma: a clinical Practice-Oriented review. Clin Pharmacol Ther. 2023;114(6):1184–1195. PMID: 37750399. doi: 10.1002/cpt.3057.
   PubMed Web of Science ®Google Scholar
• Asghari A, Nourmohammadi H, Majidiani H, et al. Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies. Environ Sci Pollut Res Int. 2022;29(22):32383–32396. PMID: 35146610. doi: 10.1007/s11356-021-17090-5.
   PubMed Web of Science ®Google Scholar
• Yue T, Zhang X, Gong P, et al. Antitumor effect of invasive Lactobacillus plantarum delivering associated antigen gene sHSP between Trichinella spiralis and lewis lung cancer cells. Int Immunopharmacol. 2023;115:109708. PMID: 36638662. doi: 10.1016/j.intimp.2023.109708.
   PubMed Web of Science ®Google Scholar
• Kang YJ, Jo JO, Cho MK, et al. Trichinella spiralis infection reduces tumor growth and metastasis of B16-F10 melanoma cells. Vet Parasitol. 2013;196(1–2):106–113. doi: 10.1016/j.vetpar.2013.02.021.PMID: 23499484.
   PubMed Web of Science ®Google Scholar
• Liao C, Cheng X, Liu M, et al. Trichinella spiralis and tumors: cause, coincidence or treatment? Anticancer Agents Med Chem. 2018;18(8):1091–1099. PMID: 29173187. doi: 10.2174/1871520617666171121115847.
   PubMed Web of Science ®Google Scholar
• Ding J, Liu X, Tang B, et al. Murine hepatoma treatment with mature dendritic cells stimulated by Trichinella spiralis excretory/secretory products. Parasite. 2020;27:47. PMID: 32692308. doi: 10.1051/parasite/2020045.
   PubMedGoogle Scholar
• Ding J, Tang B, Liu X, et al. Excretory- secretory product of Trichinella spiralis inhibits tumor cell growth by regulating the immune response and inducing apoptosis. Acta Trop. 2022;225:106172. PMID: 34627760. doi: 10.1016/j.actatropica.2021.106172.
   PubMed Web of Science ®Google Scholar
• Wang XL, Fu BQ, Yang SJ, et al. Trichinella spiralis–a potential anti-tumor agent. Vet Parasitol. 2009;159(3-4):249–252. PMID: 19041180. doi: 10.1016/j.vetpar.2008.10.052.
   PubMed Web of Science ®Google Scholar
• Wang XL, Liu MY, Sun SM, et al. An anti-tumor protein produced by Trichinella spiralis induces apoptosis in human hepatoma H7402 cells. Vet Parasitol. 2013;194(2-4):186–188. PMID: 23433602. doi: 10.1016/j.vetpar.2013.01.052.
   PubMed Web of Science ®Google Scholar
• Deng B, Gong P, Li J, et al. Identification of the differentially expressed genes in SP2/0 myeloma cells from balb/c mice infected with Trichinella spiralis. Vet Parasitol. 2013;194(2-4):179–182. PMID: 23473833. doi: 10.1016/j.vetpar.2013.01.050.
   PubMed Web of Science ®Google Scholar
• Duan L, Li J, Cheng B, et al. Identification of a novel gene product expressed by Trichinella spiralis that binds antiserum to Sp2/0 myeloma cells. Vet Parasitol. 2013;194(2-4):183–185. PMID: 23465747. doi: 10.1016/j.vetpar.2013.01.051.
   PubMed Web of Science ®Google Scholar
• Gong P, Zhang J, Cao L, et al. Identification and characterization of myeloma-associated antigens in Trichinella spiralis. Exp Parasitol. 2011;127(4):784–788. PMID: 21232537. doi: 10.1016/j.exppara.2010.12.001.
   PubMed Web of Science ®Google Scholar
• Yue TT, Zhang N, Li JH, et al. Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis. Parasit Vectors. 2021;14(1):498. PMID: 34565443. doi: 10.1186/s13071-021-05008-6.
   PubMed Web of Science ®Google Scholar
• Zhang TJ, Pang DX, Zhang N, et al. Preparation of monoclonal antibody against Trichinella spiralis selenoprotein T and its inhibitory effect on hepatoma H7402 cells in nude mice. Chin J Biologicals January. 2020;33:42–44. (in Chinese).
   Google Scholar
• Sangpheak K, Waraho-Zhmayev D, Haonoo K, et al. Investigation of interactions between binding residues and solubility of grafted humanized anti-VEGF IgG antibodies expressed as full-length format in the cytoplasm of a novel engineered E. coli SHuffle strain. RSC Adv. 2021;11(11):6035–6048. PMID: 35423148. doi: 10.1039/D0RA08534K.
   PubMed Web of Science ®Google Scholar
• Lu L, Wang X, Zhang A, et al. Selection and expression of CD40 single chain variable fragment by phage display and evaluation of tumor specific immune activation. Int Immunopharmacol. 2019;71:224–232. PMID: 30925323. doi: 10.1016/j.intimp.2019.03.020.
   PubMed Web of Science ®Google Scholar
• Murayama Y, Kawashima H, Kubo N, et al. Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. Transl Oncol. 2021;14(12):101227. PMID: 34555727. doi: 10.1016/j.tranon.2021.101227.
   PubMed Web of Science ®Google Scholar
• Noh KE, Lee JH, Choi SY, et al. TGF-β/IL-7 chimeric switch receptor-Expressing CAR-T cells inhibit recurrence of CD19-Positive B cell lymphoma. Int J Mol Sci. 2021;22(16):8706. PMID: 34445415. doi: 10.3390/ijms22168706.
   PubMed Web of Science ®Google Scholar
• Wang JP, Zhang GL, Zhang HY, et al. Screening of A549 cells-associated scFv antibody against Trichinella spiralis antigen protein 7TR. Chin J Biol. 2017;30:488–492. (in Chinese).
   Google Scholar
• Ma Y, Ma L, Guo Q, et al. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J Exp Clin Cancer Res. 2010;29(1):85. PMID: 20587070. doi: 10.1186/1756-9966-29-85.
   PubMedGoogle Scholar
• Landmann M, Scheibner D, Graaf A, et al. A semiquantitative scoring system for histopathological and immunohistochemical assessment of lesions and tissue tropism in avian influenza. Viruses. 2021;13(5):868. PMID: 34065126. doi: 10.3390/v13050868.
   PubMed Web of Science ®Google Scholar
• Xie N, Shen G, Gao W, et al. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9. PMID: 36604431. doi: 10.1038/s41392-022-01270-x.
   PubMed Web of Science ®Google Scholar
• Li J, Xiao Z, Wang D, et al. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22(1):141. PMID: 37649123. doi: 10.1186/s12943-023-01844-5.
   PubMed Web of Science ®Google Scholar
• Mahati S, Fu X, Ma X, et al. Delivery of miR-26a using an exosomes-based nanosystem inhibited proliferation of hepatocellular carcinoma. Front Mol Biosci. 2021;8:738219. PMID: 34552961. doi: 10.3389/fmolb.2021.738219.
   PubMed Web of Science ®Google Scholar
• Peng X-H, Wang Y, Huang D, et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano. 2011;5(12):9480–9493. PMID: 22032622. doi: 10.1021/nn202410f.
   PubMed Web of Science ®Google Scholar
• Vostakolaei MA, Molavi O, Hejazi MS, et al. Isolation and characterization of a novel scFv antibody fragments specific for Hsp70 as a tumor biomarker. J Cell Biochem. 2019;120(9):14711–14724. PMID: 30998271. doi: 10.1002/jcb.28732.
   PubMed Web of Science ®Google Scholar
• Lu Z, Kamat K, Johnson BP, et al. Generation of a fully human scFv that binds tumor-specific glycoforms. Sci Rep. 2019;9(1):5101. PMID: 30911061. doi: 10.1038/s41598-019-41567-6.
   PubMedGoogle Scholar
• Palmieri D, Richmond T, Piovan C, et al. Human anti-nucleolin recombinant immunoagent for cancer therapy. Proc Natl Acad Sci U S A. 2015;112(30):9418–9423. PMID: 26170308. doi: 10.1073/pnas.1507087112.
   PubMed Web of Science ®Google Scholar
• Du P, Wang X, Yin T, et al. Anti- tumor effect of single-chain antibody to Reg3a in colorectal cancer. Exp Cell Res. 2020;396(1):112278. PMID: 32918897. doi: 10.1016/j.yexcr.2020.112278.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287. PMID: 22437872. doi: 10.1038/nrc3236.
   PubMed Web of Science ®Google Scholar
• Ludwig DL, Pereira DS, Zhu Z, et al. Monoclonal antibody therapeutics and apoptosis. Oncogene. 2003;22(56):9097–9106. PMID: 14663488. doi: 10.1038/sj.onc.1207104.
   PubMed Web of Science ®Google Scholar
• Muratori L, Gnavi S, Fregnan F, et al. Evaluation of vascular endothelial growth factor (VEGF) and its family member expression after peripheral nerve regeneration and denervation. Anat Rec. 2018;301(10):1646–1656. PMID: 29710417. doi: 10.1002/ar.23842.
   Google Scholar
• He S, Zhao C, Tao H, et al. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Deliv. 2022;29(1):1243–1256. PMID: 35416106. doi: 10.1080/10717544.2022.2063454.
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Achuthanandam R, Capocasale RJ, et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499–521. PMID: 20477639. doi: 10.1586/eci.09.31.
   PubMed Web of Science ®Google Scholar
• Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89. PMID: 28407743. doi: 10.1186/s13054-017-1678-1.
   PubMed Web of Science ®Google Scholar
• Lin XR, Zhou XL, Feng Q, et al. CIK cell- based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer. J Cancer Res Clin Oncol. 2019;145(5):1123–1132. PMID: 30796510. doi: 10.1007/s00432-019-02857-8.
   PubMed Web of Science ®Google Scholar
• Li YR, Halladay T, Yang L. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies. J Biomed Sci. 2024;31(1):5. PMID: 38217016. doi: 10.1186/s12929-024-00998-8.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25(1):267–296. PMID: 17134371. doi: 10.1146/annurev.immunol.25.022106.141609.
   PubMed Web of Science ®Google Scholar
• Passaro A, Jänne PA, Peters S. Antibody-drug conjugates in lung cancer: recent advances and implementing strategies. J Clin Oncol. 2023;41(21):3747–3761. PMID: 37224424. doi: 10.1200/jco.23.00013.
   PubMed Web of Science ®Google Scholar
• Reck M, Garassino MC, Imbimbo M, et al. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018;120:62–69. doi: 10.1016/j.lungcan.2018.03.025.
   PubMed Web of Science ®Google Scholar